Literature DB >> 17225928

Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report.

Salvatore Corrao1, Giovanni Pistone, Sabrina Arnone, Luigi Calvo, Rosario Scaglione, Giuseppe Licata.   

Abstract

This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benefit of this treatment to establish together with patients if etanercept therapy has to be discontinued before and after elective surgery. Finally, we think that adverse drug reaction surveillance has to be boosted, and editors of leading scientific journal should publish more papers on case-series about drug safety and tolerability in particular conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225928     DOI: 10.1007/s10067-007-0534-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

Review 1.  What are the advances for surgical therapy of inflammatory diseases of the spine?

Authors:  Marek Szpalski; R Gunzburg
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-01       Impact factor: 4.098

2.  Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data.

Authors:  A Jain; R Maini; J Nanchahal
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

Review 3.  [New methods for studying drug associated risk: experience of the Toulouse Regional Pharmacovigilance Center].

Authors:  Jean-Louis Montastruc; Haleh Bagheri; Isabelle Lacroix; Pascale Olivier; Genevieve Durrieu; Christine Damase-Michel; Maryse Lapeyre-Mestre
Journal:  Bull Acad Natl Med       Date:  2005-03       Impact factor: 0.144

4.  Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.

Authors:  S Schreiber; M Campieri; J F Colombel; S J van Deventer; B Feagan; R Fedorak; A Forbes; M Gassull; J P Gendre; R A van Hogezand; R Lofberg; R Modigliani; F Pallone; W Petritsch; C Prantera; D Rampton; F Seibold; M Vatn; M Zeitz; P Rutgeerts
Journal:  Int J Colorectal Dis       Date:  2001-02       Impact factor: 2.571

Review 5.  Interventions for foot disease in rheumatoid arthritis: a systematic review.

Authors:  S J Farrow; G H Kingsley; D L Scott
Journal:  Arthritis Rheum       Date:  2005-08-15

Review 6.  Emerging biologic drugs for the treatment of rheumatoid arthritis.

Authors:  Francesco Puppo; Giuseppe Murdaca; Massimo Ghio; Francesco Indiveri
Journal:  Autoimmun Rev       Date:  2005-11       Impact factor: 9.754

7.  Immune function in patients with rheumatoid arthritis treated with etanercept.

Authors:  L W Moreland; R P Bucy; M E Weinblatt; K M Mohler; G T Spencer-Green; W W Chatham
Journal:  Clin Immunol       Date:  2002-04       Impact factor: 3.969

Review 8.  Revision total knee arthroplasty: planning, controversies, and management--infection.

Authors:  S Munjal; M J Phillips; K A Krackow
Journal:  Instr Course Lect       Date:  2001

Review 9.  Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.

Authors:  Roy M Fleischmann; Imran Iqbal; Richard L Stern
Journal:  Expert Opin Drug Saf       Date:  2004-09       Impact factor: 4.250

10.  Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.

Authors:  Christopher Bibbo; Jerry W Goldberg
Journal:  Foot Ankle Int       Date:  2004-05       Impact factor: 2.827

  10 in total
  3 in total

1.  Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk?

Authors:  Daniel Wendling
Journal:  Clin Rheumatol       Date:  2007-02-21       Impact factor: 2.980

2.  Cachexia - an intrinsic factor in wound healing.

Authors:  Michael F Y Ng
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

Review 3.  Preoperative Evaluation and Management of Patients Receiving Biologic Therapies.

Authors:  Zahra Rezaieyazdi; Maryam Sahebari; Mandana Khodashahi
Journal:  Arch Bone Jt Surg       Date:  2019-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.